Acquisition of anoikis resistance promotes the emergence of oncogenic K-ras mutations in colorectal cancer cells and stimulates their tumorigenicity in vivo

被引:38
作者
Derouet, Mathieu
Wu, Xue
May, Linda
Yoo, Byong Hoon
Sasazuki, Takehiko
Shirasawa, Senji
Rak, Janusz
Rosen, Kirill V.
机构
[1] Dalhousie Univ, Atlantic Res Ctr, Dept Pediat, Halifax, NS B3H 4H7, Canada
[2] Dalhousie Univ, Atlantic Res Ctr, Dept Biochem & Mol Biol, Halifax, NS B3H 4H7, Canada
[3] McMaster Univ, Henderson Res Ctr, Hamilton, ON, Canada
[4] Int Med Ctr Japan, Res Inst, Dept Pathol, Tokyo, Japan
[5] Fukuoka Univ, Sch Med, Dept Cell Biol, Fukuoka 81401, Japan
[6] McGill Univ, Montreal Childrens Hosp, Res Inst, Dept Pediat, Montreal, PQ H3H 1P3, Canada
来源
NEOPLASIA | 2007年 / 9卷 / 07期
基金
加拿大健康研究院;
关键词
colorectal cancer; ras; anoikis; apoptosis; extracellular matrix;
D O I
10.1593/neo.07217
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Detachment from the extracellular matrix causes apoptosis of normal epithelial cells-a phenomenon called anoikis. K-ras oncogene, an established anoikis inhibitor, often occurs in colorectal carcinoma (CRC). In addition to blocking anoikis-inducing mechanisms, oncogenic K- ras can cause anoikis-unrelated changes in CRC cells, such as induction of events promoting their deregulated mitogenesis, ability to trigger angiogenesis, and so on. Thus, whether ras-induced anoikis resistance of CRC cells is essential for their ability to form tumors in vivo or represents a mere epiphenomenon is unclear. We found that when poorly tumorigenic, oncogenic, K- ras - negative, anoikis-susceptible human CRC cells were cultured under anoikis- inducing conditions in vitro, they spontaneously gave rise to an anoikis-resistant cell population harboring de novo oncogenic K-ras mutations and manifesting dramatically increased tumorigenicity. We further observed that a variant of the same oncogenic K-ras-negative anoikis-susceptible cells selected for increased tumorigenicity acquired de novo oncogenic K-ras mutations and manifested increased anoikis resistance. Unlike the case with anoikis, oncogenic K-ras did not rescue CRC cells from death caused by hypoxia or anticancer agents. Taken collectively, our results support the notion that ras-induced anoikis resistance of CRC cells is essential for their ability to form tumors in vivo and thus represents a potential therapeutic target.
引用
收藏
页码:536 / 545
页数:10
相关论文
共 34 条
[1]   Increased expression of apoptosis inhibitor protein XIAP contributes to anoikis resistance of circulating human prostate cancer metastasis precursor cells [J].
Berezovskaya, O ;
Schimmer, AD ;
Glinskii, AB ;
Pinilla, C ;
Hoffman, RM ;
Reed, JC ;
Glinsky, GV .
CANCER RESEARCH, 2005, 65 (06) :2378-2386
[2]   PREVALENCE OF RAS GENE-MUTATIONS IN HUMAN COLORECTAL CANCERS [J].
BOS, JL ;
FEARON, ER ;
HAMILTON, SR ;
VERLAANDEVRIES, M ;
VANBOOM, JH ;
VANDEREB, AJ ;
VOGELSTEIN, B .
NATURE, 1987, 327 (6120) :293-297
[3]   Disruption of p53 in human cancer cells alters the responses to therapeutic agents [J].
Bunz, F ;
Hwang, PM ;
Torrance, C ;
Waldman, T ;
Zhang, YG ;
Dillehay, L ;
Williams, J ;
Lengauer, C ;
Kinzler, KW ;
Vogelstein, B .
JOURNAL OF CLINICAL INVESTIGATION, 1999, 104 (03) :263-269
[4]   Requirement for p53 and p21 to sustain G2 arrest after DNA damage [J].
Bunz, F ;
Dutriaux, A ;
Lengauer, C ;
Waldman, T ;
Zhou, S ;
Brown, JP ;
Sedivy, JM ;
Kinzler, KW ;
Vogelstein, B .
SCIENCE, 1998, 282 (5393) :1497-1501
[5]   Targeted inactivation of CTNNB1 reveals unexpected effects of β-catenin mutation [J].
Chan, TA ;
Wang, ZH ;
Dang, LH ;
Vogelstein, B ;
Kinzler, KW .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2002, 99 (12) :8265-8270
[6]   Suppression of anoikis and induction of metastasis by the neurotrophic receptor TrkB [J].
Douma, S ;
van Laar, T ;
Zevenhoven, J ;
Meuwissen, R ;
van Garderen, E ;
Peeper, DS .
NATURE, 2004, 430 (7003) :1034-1040
[7]   A GENETIC MODEL FOR COLORECTAL TUMORIGENESIS [J].
FEARON, ER ;
VOGELSTEIN, B .
CELL, 1990, 61 (05) :759-767
[8]   Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer [J].
Ferrara, N ;
Hillan, KJ ;
Gerber, HP ;
Novotny, W .
NATURE REVIEWS DRUG DISCOVERY, 2004, 3 (05) :391-400
[9]  
FILMUS J, 1994, ONCOGENE, V9, P3627
[10]   DISRUPTION OF EPITHELIAL CELL-MATRIX INTERACTIONS INDUCES APOPTOSIS [J].
FRISCH, SM ;
FRANCIS, H .
JOURNAL OF CELL BIOLOGY, 1994, 124 (04) :619-626